Iran's Pasteur Institute Resumes Vaccine Production After Missile Strikes

TEHRAN, Iran (AP) — The Pasteur Institute of Iran has resumed vaccine production and essential health services following damage from recent missile strikes attributed to the United States and Israel. The facility, located in Tehran, continues operations despite ongoing security concerns and infrastructure challenges.

The institute, a key player in Iran's public health system, reported that critical manufacturing lines were restored within days of the attacks. Officials stated that the resumption of services is vital to maintain national immunization programs and prevent disruptions to disease prevention efforts. The strikes, which occurred earlier this month, targeted several sites across the country, including the institute's research and production facilities.

Damage assessments indicate that while some laboratories and storage units were compromised, the core production infrastructure remained functional. Emergency repairs were carried out by technical teams working around the clock to restore power and ventilation systems. The institute emphasized that no personnel were injured during the attacks, though several staff members were temporarily evacuated.

Iranian health authorities have not confirmed the extent of the damage or the specific nature of the attacks. However, the Pasteur Institute has publicly acknowledged the incident and outlined its recovery efforts. The facility remains under heightened security measures, with access restricted to essential personnel only.

The United States and Israel have not officially commented on the targeting of the Pasteur Institute. Previous statements from both nations have focused on broader strategic objectives in the region, without detailing specific civilian or medical targets. The lack of official acknowledgment has left questions about the intent and scope of the strikes.

Public health experts warn that disruptions to vaccine production could have significant consequences for regional disease control. The institute produces vaccines for polio, hepatitis, and other preventable illnesses, serving millions across Iran and neighboring countries. Any prolonged interruption could strain public health systems and increase the risk of outbreaks.

As of Saturday, the institute has confirmed that limited production has resumed, with full capacity expected to return within weeks. However, the long-term impact on research and development remains uncertain. The facility's ability to maintain its role in regional health security will depend on continued stability and the absence of further attacks.

The situation remains fluid, with no official timeline for the full restoration of all services. International health organizations are monitoring the situation closely, though no formal statements have been issued regarding the incident. The Pasteur Institute has not indicated whether it will seek external assistance or cooperation in its recovery efforts.

Questions remain about the future of the facility and the broader implications for public health in the region. As tensions persist, the resilience of Iran's medical infrastructure will be tested in the coming weeks.